24-Hour ambulatory blood pressure response to combination valsartan/hydrochlorothiazide and amlodipine/hydrochlorothiazide in stage 2 hypertension by ethnicity: The EVALUATE study

Journal of Clinical Hypertension

Volumn 12, Issue 11, 2010, Pages 833-840

  Wright, Jackson T ^a   Lacourcière, Yves ^b   Samuel, Rita ^c   Zappe, Dion ^c   Purkayastha, Das ^c   Black, Henry R ^d  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LAVAL UNIVERSITY   (Canada)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN;

ADULT; AFRICAN AMERICAN; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CAUCASIAN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE TITRATION; DRUG MEGADOSE; ETHNICITY; FEMALE; GLOMERULUS FILTRATION RATE; HEADACHE; HISPANIC; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NIGHT; PERIPHERAL EDEMA; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 78249255514     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2010.00372.x     Document Type: Article

References (28)

1. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75.
2. Ferdinand KC, Ferdinand DP. Race-based therapy for hypertension: possible benefits and potential pitfalls. Expert Rev Cardiovasc Ther. 2008;6:1357-1366.
3. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
4. McWilliams JM, Meara E, Zaslavsky AM, et al. Differences in control of cardiovascular disease and diabetes by race, ethnicity, and education: U.S. trends from 1999 to 2006 and effects of medicare coverage. Ann Intern Med. 2009;150:505-515.
5. Park IU, Taylor AL. Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review. Ann Fam Med. 2007;5:444-452.
6. Khan JM, Beevers DG. Management of hypertension in ethnic minorities. Heart. 2005;91:1105-1109.
7. Wright JT Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293:1595-1608.
8. Johnson E, Wright JT Jr. Management of hypertension in black populations. In: Oparil S, Weber M, eds. Hypertension. Philadelphia, PA: Elsevier Saunders; 2005: 587-595.
9. Natarajan S, Santa Ana EJ, Liao Y, et al. Effect of treatment and adherence on ethnic differences in blood pressure control among adults with hypertension. Ann Epidemiol. 2009;19:172-179.
10. Margolis KL, Piller LB, Ford CE, et al. Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2007;50:854-861.
11. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
12. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163:525-541.
13. Khan NA, Hemmelgarn B, Herman RJ, Bell CM, Mahon JL, Leiter LA, Rabkin SW, Hill MD, Padwal R, Touyz RM, Larochelle P, Feldman RD, Schiffrin EL, Campbell NR, Moe G, Prasad R, Arnold MO, Campbell TS, Milot A, Stone JA, Jones C, Ogilvie RI, Hamet P, Fodor G, Carruthers G, Burns KD, Ruzicka M, DeChamplain J, Pylypchuk G, Petrella R, Boulanger JM, Trudeau L, Hegele RA, Woo V, McFarlane P, Vallée M, Howlett J, Bacon SL, Lindsay P, Gilbert RE, Lewanczuk RZ, Tobe S; Canadian Hypertension Education Program. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. Can J Cardiol. 2009;25:287-298.
14. National Collaborating Centre for Chronic Conditions. Hypertension: Management in Adults in Primary Care: Pharmacological Update. London, UK: Royal College of Physicians; 2006.
15. Lacourcière Y, Wright JT Jr, Samuel R, et al. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study. Blood Press Monit. 2009;14:112-120.
16. Preston RA, Materson BJ, Reda DJ, et al. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. JAMA. 1998;280:1168-1172.
17. Nguyen TT, Kaufman JS, Whitsel EA, et al. Racial differences in blood pressure response to calcium channel blocker monotherapy: a meta-analysis. Am J Hypertens. 2009;22:911-917.
18. Brouwer RM, Bolli P, Erne P, et al. Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. J Cardiovasc Pharmacol. 1985;7(suppl 1):S88-S91.
19. Massie B, MacCarthy EP, Ramanathan KB, et al. Diltiazem and propranolol in mild to moderate essential hypertension as monotherapy or with hydrochlorothiazide. Ann Intern Med. 1987;107:150-157.
20. Burris JF, Weir MR, Oparil S, et al. An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy. JAMA. 1990;263:1507-1512.
21. Elliott WJ, Polascik TB, Murphy MB. Equivalent antihypertensive effects of combination therapy using diuretic + calcium antagonist compared with diuretic + ACE inhibitor. J Hum Hypertens. 1990;4:717-723.
22. Manning G, Joy A, Mathias CJ, et al. Double-blind, parallel, comparative multicentre study of a new combination of diltiazem and hydrochlorothiazide with individual components in patients with mild or moderate hypertension. J Hum Hypertens. 1996;10:443-448.
23. Ferdinand KC, Saunders E. Hypertension-related morbidity and mortality in African Americans - why we need to do better. J Clin Hypertens (Greenwich). 2006;1(suppl 1):21-30.
24. Saunders E, Weir MR, Kong BW, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150:1707-1713.
25. Materson BJ. Lessons on the interaction of race and antihypertensive drugs from the VA cooperative study group on antihypertensive agents. Am J Hypertens. 1995;8:91s-93s.
26. Cooper-DeHoff RM, Aranda JM Jr, et al. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients--findings from the International Verapamil SR/Trandolapril Study (INVEST). Am Heart J. 2006;151:1072-1079.
27. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.
28. Gadegbeku CA, Lea JP, Jamerson KA. Update on disparities in the pathophysiology and management of hypertension: focus on African Americans. Med Clin North Am. 2005;89:921-33.